BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 8247532)

  • 1. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage.
    Aloni-Grinstein R; Zan-Bar I; Alboum I; Goldfinger N; Rotter V
    Oncogene; 1993 Dec; 8(12):3297-305. PubMed ID: 8247532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins.
    Shaulsky G; Goldfinger N; Rotter V
    Cancer Res; 1991 Oct; 51(19):5232-7. PubMed ID: 1717142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-kappaB, but not c-Jun N-terminal kinase and activated protein-1.
    Gulati AP; Yang YM; Harter D; Mukhopadhyay A; Aggarwal BB; Benzil DL; Whysner J; Albino AP; Murali R; Jhanwar-Uniyal M
    Mol Carcinog; 2006 Jan; 45(1):26-37. PubMed ID: 16267831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild-type murine p53 represses transcription from the murine c-myc promoter in a human glial cell line.
    Moberg KH; Tyndall WA; Hall DJ
    J Cell Biochem; 1992 Jun; 49(2):208-15. PubMed ID: 1400626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-Methylcholanthrene inactivates the p53 gene in Syrian hamster embryo fibroblasts by inducing a specific intronic point mutation.
    Albor A; Flessate DM; Soussi T; Notario V
    Cancer Res; 1994 Aug; 54(16):4502-7. PubMed ID: 8044802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of p53 transactivation through high-affinity binding sites.
    Chumakov AM; Miller CW; Chen DL; Koeffler HP
    Oncogene; 1993 Nov; 8(11):3005-11. PubMed ID: 8414502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53.
    Zastawny RL; Salvino R; Chen J; Benchimol S; Ling V
    Oncogene; 1993 Jun; 8(6):1529-35. PubMed ID: 8502478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does wild-type p53 play a role in normal cell differentiation?
    Rotter V; Aloni-Grinstein R; Schwartz D; Elkind NB; Simons A; Wolkowicz R; Lavigne M; Beserman P; Kapon A; Goldfinger N
    Semin Cancer Biol; 1994 Jun; 5(3):229-36. PubMed ID: 7948951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of prostate specific antigen (PSA) is negatively regulated by p53.
    Gurova KV; Roklin OW; Krivokrysenko VI; Chumakov PM; Cohen MB; Feinstein E; Gudkov AV
    Oncogene; 2002 Jan; 21(1):153-7. PubMed ID: 11791186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 promotes selection for Fas-mediated apoptotic resistance.
    Maecker HL; Koumenis C; Giaccia AJ
    Cancer Res; 2000 Aug; 60(16):4638-44. PubMed ID: 10969818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents.
    Grombacher T; Eichhorn U; Kaina B
    Oncogene; 1998 Aug; 17(7):845-51. PubMed ID: 9780001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of genes whose expressions are altered in rat 6 fibroblasts transformed by mutant p53(val135).
    Yam JW; Zheng JY; Hsiao WL
    Biochem Biophys Res Commun; 1999 Dec; 266(2):472-80. PubMed ID: 10600527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proliferation-associated early response gene p22/PRG1 is a novel p53 target gene.
    Schäfer H; Trauzold A; Sebens T; Deppert W; Fölsch UR; Schmidt WE
    Oncogene; 1998 May; 16(19):2479-87. PubMed ID: 9627114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional regulation of the Ig kappa gene by promoter-proximal pausing of RNA polymerase II.
    Raschke EE; Albert T; Eick D
    J Immunol; 1999 Oct; 163(8):4375-82. PubMed ID: 10510378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 involvement in activation of the cytokeratin 8 gene in tumor cell lines.
    Mukhopadhyay T; Roth JA
    Anticancer Res; 1996; 16(1):105-12. PubMed ID: 8615594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular cloning and functional analysis of the promoter region of rat nonmuscle myosin heavy chain-B gene.
    Yam JW; Chan KW; Li N; Hsiao WL
    Biochem Biophys Res Commun; 2000 Oct; 276(3):1203-9. PubMed ID: 11027611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
    Liang Y; Wu J; Stancel GM; Hyder SM
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells.
    Sun SY; Yue P; Hong WK; Lotan R
    Cancer Res; 2000 Nov; 60(22):6537-43. PubMed ID: 11103825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of the tumor suppressor gene p53 in tumor necrosis factor-induced differentiation of the leukemic cell line K562.
    Ehinger M; Nilsson E; Persson AM; Olsson I; Gullberg U
    Cell Growth Differ; 1995 Jan; 6(1):9-17. PubMed ID: 7718488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.